CL2020003189A1 - Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión - Google Patents

Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Info

Publication number
CL2020003189A1
CL2020003189A1 CL2020003189A CL2020003189A CL2020003189A1 CL 2020003189 A1 CL2020003189 A1 CL 2020003189A1 CL 2020003189 A CL2020003189 A CL 2020003189A CL 2020003189 A CL2020003189 A CL 2020003189A CL 2020003189 A1 CL2020003189 A1 CL 2020003189A1
Authority
CL
Chile
Prior art keywords
bupropion
methods
plasma levels
tetrabenazine
dihydrotetrabenazine
Prior art date
Application number
CL2020003189A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CL2020003189A1 publication Critical patent/CL2020003189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación se refiere a métodos que administran bupropión, como S-bupropión o R-bupropión, junto con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazina a un ser humano. También se describen formas de dosificación, sistemas de administración de fármacos y métodos relacionados con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazina y bupropión, como S-bupropión o R-bupropión.
CL2020003189A 2018-06-10 2020-12-07 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión CL2020003189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682998P 2018-06-10 2018-06-10
US201862683399P 2018-06-11 2018-06-11

Publications (1)

Publication Number Publication Date
CL2020003189A1 true CL2020003189A1 (es) 2021-05-28

Family

ID=68843534

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003189A CL2020003189A1 (es) 2018-06-10 2020-12-07 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Country Status (17)

Country Link
EP (1) EP3790538A4 (es)
JP (2) JP2021529826A (es)
KR (2) KR20210018914A (es)
CN (1) CN112292121A (es)
AU (2) AU2019284477B2 (es)
BR (1) BR112020025064A2 (es)
CA (1) CA3101375A1 (es)
CL (1) CL2020003189A1 (es)
CO (1) CO2021000037A2 (es)
CR (1) CR20200616A (es)
EC (1) ECSP20082568A (es)
IL (1) IL279332A (es)
MX (1) MX2020013385A (es)
NI (1) NI202000095A (es)
PE (1) PE20210370A1 (es)
SG (1) SG11202011762VA (es)
WO (1) WO2019241162A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
JP2005510449A (ja) * 2001-02-08 2005-04-21 アンドルックス ファーマスーティカルズ インコーポレーテッド 改良型制御放出経口剤形
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US10105327B2 (en) * 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9707191B2 (en) * 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
AU2016229949B2 (en) * 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
KR20240125709A (ko) * 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제

Also Published As

Publication number Publication date
CA3101375A1 (en) 2019-12-19
EP3790538A1 (en) 2021-03-17
AU2019284477A1 (en) 2021-01-28
JP2024059744A (ja) 2024-05-01
IL279332A (en) 2021-01-31
KR20240034871A (ko) 2024-03-14
ECSP20082568A (es) 2021-02-26
JP2021529826A (ja) 2021-11-04
AU2022268331B2 (en) 2024-11-14
BR112020025064A2 (pt) 2021-03-23
CR20200616A (es) 2021-03-15
CO2021000037A2 (es) 2021-01-18
SG11202011762VA (en) 2020-12-30
AU2022268331A1 (en) 2022-12-15
KR20210018914A (ko) 2021-02-18
EP3790538A4 (en) 2021-06-30
PE20210370A1 (es) 2021-02-26
WO2019241162A1 (en) 2019-12-19
NI202000095A (es) 2021-06-22
AU2019284477B2 (en) 2022-08-11
MX2020013385A (es) 2021-05-27
CN112292121A (zh) 2021-01-29

Similar Documents

Publication Publication Date Title
CL2020003174S1 (es) Dispositivo para administración de dosis.
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
ECSP19084085A (es) Inhibidores pirazólicos de magl
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2019000946A (es) Administracion y dosificacion de diaminofenotiazinas.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2021003830A (es) Uso terapéutico del glucagón y combinación que incluye el mismo.
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
MX390755B (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021007177A (es) Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CO2021000037A2 (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR118756A1 (es) Anticuerpos y formulaciones de anti-cd38
UA135395U (uk) Комбінований лікарський засіб снодійной дії